U.S. Pharma Stock News

If you are wondering whether Kraft Heinz is a bargain or a value trap at around US$23.66, this article breaks down what that price really implies for you. The stock has recently returned 4.4% over the last week and 2.1% over the last month, yet is still showing a 3.0% decline year to date and an 11.7% decline over the past year. Recent coverage has focused on Kraft Heinz as a mature packaged food giant that investors often look to for stability, which can attract attention when prices move...

Wondering whether agilon health’s recent action has left the stock looking expensive or still potentially mispriced? This article breaks down what the current price might be implying about its value. The stock last closed at US$60.66, with returns of 117.0% over 7 days, 265.6% over 30 days and 260.2% year to date. The 1 year and 3 year returns stand at negative 24.6% and negative 90.4% respectively. These sharp moves are drawing attention back to agilon health, especially as investors weigh...

Wondering if State Street stock still offers value after a strong run, or if most of the opportunity is already reflected in the price? This article focuses squarely on what you are paying for each dollar of fundamentals. At a recent close of US$148.78, the stock has returned 13.4% over the past month, 15.3% year to date, and 62.6% over the last year, with a 2.7% decline in the last week and longer term 3 year and 5 year returns of 142.5% and 103.6%. Recent headlines around large financial...

Why Astronics Stock Is Back in Focus Astronics (ATRO) is back on investors’ radar after a strong price trend, supported by positive earnings estimate revisions and favorable analyst opinions. The stock is now trading close to its 52-week high. See our latest analysis for Astronics. The recent momentum is clear, with a 7-day share price return of 9.17% and a year to date share price return of 37.70%. The 1-year total shareholder return is very large, and the 3-year total shareholder return is...

Bio-Techne Corporation reported its fiscal third-quarter 2026 results in early May, with net sales of US$311.42 million, a 2% year-over-year decline, while net income rose to US$51.05 million and diluted EPS from continuing operations increased to US$0.32. Alongside softer demand from emerging biotech customers and shipment timing issues that weighed on revenue, Bio-Techne’s profitability improved and the Board affirmed a quarterly cash dividend of US$0.08 per share, highlighting an ongoing...

Wondering if Bunge Global is reasonably priced after a strong run, or if the stock might already reflect a lot of good news? This article focuses squarely on what you are paying versus what you might be getting. The stock most recently closed at US$123.75, with a 33.6% year to date return and a 67.3% return over 1 year, following a 2.6% decline over both the last 7 days and the last 30 days. Recent coverage has highlighted Bunge Global's role in the global food and agriculture supply chain,...

Wondering if GXO Logistics at around US$51.88 is offering you value right now, or if the recent price action has already reflected most of the upside? The stock has pulled back, with a 9.2% decline over the last week and a 2.6% decline over the last month, while the 1 year return sits at 30.6% and the 3 year return at a 4.9% decline. Recent coverage has focused on how GXO Logistics fits into broader logistics and supply chain themes, as investors reassess the sector after a strong 1 year...

US Foods Holding Corp. ( NYSE:USFD ) shareholders are probably feeling a little disappointed, since its shares fell...

In early May 2026, Workiva Inc. reported first-quarter revenue of US$247.31 million, up from US$206.28 million a year earlier, and moved from a US$21.37 million net loss to a US$19 million net profit. The company also issued guidance calling for Q2 2026 revenue of US$250 million to US$252 million and full-year 2026 revenue of US$1.04 billion at the midpoint, while announcing a transition from Ernst & Young to Grant Thornton as its independent auditor without any reported disputes. Next,...

Limbach Holdings (LMB) is in focus after its Q1 2026 report showed sales of US$138.86 million, net income of US$4.38 million and reaffirmed full year revenue guidance of US$730 million to US$760 million. See our latest analysis for Limbach Holdings. The share price has pulled back sharply in the very short term, with a 7 day share price return of a 25.7% decline and a 1 year total shareholder return of a 38.19% decline, even after very large 3 and 5 year total shareholder gains. This suggests...

In the first quarter ended March 31, 2026, Jones Lang LaSalle reported higher sales of US$6,386.5 million and net income of US$159.0 million, while also completing a long-running US$1.70 billion share repurchase program and arranging major hotel sale and financing transactions in Florida. Together, the stronger quarterly results, sizable buybacks, and high-profile hospitality financing deals underline how JLL is leaning on fee-based advisory strength and capital allocation to reshape its...

In early May 2026, RH was caught in a broad sell-off affecting specialty retailers as rising oil, gasoline, and freight costs raised concerns about consumer discretionary spending and retailer margins ahead of the back-to-school season. The pressure on RH highlights how macroeconomic cost headwinds, rather than company-specific developments, can quickly reshape sentiment toward higher-end discretionary brands. We’ll now examine how this sector-wide cost pressure and consumer spending concern...

It's been a pretty great week for Evolent Health, Inc. ( NYSE:EVH ) shareholders, with its shares surging 14% to...

TransUnion ( NYSE:TRU ) announced strong profits, but the stock was stagnant. We did some digging, and we found some...

Alpha Teknova, Inc. ( NASDAQ:TKNO ) defied analyst predictions to release its quarterly results, which were ahead of...

It's been a good week for Xeris Biopharma Holdings, Inc. ( NASDAQ:XERS ) shareholders, because the company has just...

Global markets are on edge, with inflation, interest rate expectations, energy prices, and geopolitics all competing for attention, yet many investors still want income that feels relatively steady. That is where high yield dividend fortresses come in: stocks offering 5%+ dividend yields and balance sheet strength that can help keep payouts at the center of your plan. Rather than chasing the hottest story, this screener focuses on resilience and cash returns. In this article, you will see...

Clearway Energy (CWEN) closed out FY 2025 with Q4 revenue of US$310 million and a basic EPS loss of US$0.85, set against trailing 12 month EPS of US$1.42 and net income of US$169 million that lifted the net margin to 11.8% from 6.4% a year earlier. Over recent quarters, the company has seen revenue move from US$298 million in Q1 2025 to a peak of US$429 million in Q3 2025, while quarterly EPS ranged from US$0.03 in Q1 to US$2.00 in Q3 before the Q4 loss. This leaves investors focused on how...

Solid Power (SLDP) is in focus after reporting first quarter 2026 results alongside progress on its electrolyte commercialization plans, giving you fresh numbers and project updates to weigh against the current share price. See our latest analysis for Solid Power. Solid Power’s recent earnings update, electrolyte progress with SK On and Samsung SDI, and funding raise come after a volatile period, with a 1-day share price return of negative 12.71% and a 1-year total shareholder return of very...

Netskope (NasdaqGS:NTSK) has introduced AgentSkope, an AI-driven agentic operations platform for automating security and network workflows. The new platform brings a suite of AI-powered agents designed to handle routine and complex operational tasks for security and network teams. This launch adds a fresh product to Netskope's portfolio in automated cybersecurity operations, an area where many enterprises are seeking more efficiency. Netskope trades at $11.4, with the stock showing a 14.5%...

Caris Life Sciences (CAI) closed FY 2025 with Q4 revenue of US$292.9 million and basic EPS of US$0.29, alongside trailing 12 month revenue of US$812.0 million and a trailing basic EPS loss of US$3.22, set against a 97% year over year revenue increase and expectations for earnings to grow about 70.5% per year with profitability projected within three years. Over recent periods, the company has seen quarterly revenue move from US$101.6 million in Q3 2024 to US$129.9 million in Q4 2024, then to...

In early May 2026, Freshpet reported first-quarter net sales of US$297.64 million, a swing to net income of US$48.51 million and higher full-year 2026 net sales growth guidance to 8%–11%. Beyond the headline numbers, the return to profitability alongside raised sales expectations suggests that Freshpet’s operational changes and brand investments are starting to translate into financial progress. With Freshpet now profitable and lifting its 2026 sales outlook, we’ll examine how this improved...

As you might know, Primoris Services Corporation ( NYSE:PRIM ) last week released its latest first-quarter, and things...

Corcept Therapeutics reported long term survival data from its DAZALS Phase 2 trial of dazucorilant in ALS. Patients receiving 300 mg daily experienced an 87% reduction in risk of death at two years. The trial did not meet its primary functional endpoint, but the survival benefit attracted attention at the ENCALS 2025 meeting. For investors tracking NasdaqCM:CORT, this new ALS data adds another layer to the story around Corcept Therapeutics beyond its core cortisol modulation work. The...